Logo of jvirolLink to Publisher's site
PMC full text:
Copyright/LicenseRequest permission to reuse

FIG. 6.

An external file that holds a picture, illustration, etc. Object name is zjv0200683120006.jpg

Local delivery of mrIFN-β provides innate protection against vaginal HSV-2 challenge of B6 and IRF-3−/− mice. Six- to eight-week-old female IRF-3−/− mice (n = 8) or control B6 mice (n = 10) were treated with cell supernatants containing mrIFN-β (mrIFN-β sup) or mock supernatants (mock sup) or left untreated. Twenty-four hours posttreatment, mice were challenged with IVAG HSV-2. Challenged mice were monitored daily for genital pathology and survival. Local delivery of mrIFN-β provided B6 mice with 80% protection and IRF-3−/− mice with 75% protection against subsequent IVAG HSV-2 challenge. Mice treated with mock supernatants showed no protection against IVAG HSV-2 challenge compared to naïve mice.

Images in this article

  • FIG. 1.
  • FIG. 2.
  • FIG. 3.
  • FIG. 4.
  • FIG. 5.
  • FIG. 6.
Click on the image to see a larger version.